Floatz logo

FILGRASTIM

Acute on Chronic Hepatic Failure

Institute of Liver and Biliary Sciences, Indiaprotein_peptidePhase 3Dormant
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Acute on Chronic Hepatic Failure cohort.

Asset / SponsorPhaseRating
Erythropoietin Human Recombinant
Institute of Liver and Biliary Sciences, India
Phase 3BB
Emricasan
Conatus Pharmaceuticals Inc.
Phase 2CCC
Plavix
Hepa Wash GmbH
N/AD
Spironolactone
Hepa Wash GmbH
N/AD
Acetylsalicylic Acid
Hepa Wash GmbH
N/AD
FUROSEMIDE
Hepa Wash GmbH
N/AD

Same molecule, other indications

FILGRASTIM is also rated in:

plasma cell myelomaDormant
BBB
Indicative ·
79 / 100
View asset →
Burkitt lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →